PL2970412T3 - Aktywacja bioluminescencji przez dopełnienie strukturalne - Google Patents

Aktywacja bioluminescencji przez dopełnienie strukturalne

Info

Publication number
PL2970412T3
PL2970412T3 PL14769752.8T PL14769752T PL2970412T3 PL 2970412 T3 PL2970412 T3 PL 2970412T3 PL 14769752 T PL14769752 T PL 14769752T PL 2970412 T3 PL2970412 T3 PL 2970412T3
Authority
PL
Poland
Prior art keywords
bioluminscence
activation
structural complement
complement
structural
Prior art date
Application number
PL14769752.8T
Other languages
English (en)
Polish (pl)
Inventor
Andrew S. Dixon
Lance Encell
Mary Hall
Keith Wood
Monika Wood
Marie SCHWINN
Brock F. Binkowski
Hicham Zegzouti
Nidhi Nath
Subhanjan Mondal
Said Goueli
Poncho Meisenheimer
Thomas Kirkland
James Unch
Dileep K. Pulukkunat
Matthew Robers
Melanie Dart
Thomas Machleidt
Original Assignee
Promega Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promega Corporation filed Critical Promega Corporation
Publication of PL2970412T3 publication Critical patent/PL2970412T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0283—Price estimation or determination
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/06—Buying, selling or leasing transactions
    • G06Q30/0601—Electronic shopping [e-shopping]
    • G06Q30/0631—Recommending goods or services
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/02—Services making use of location information
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/30—Services specially adapted for particular environments, situations or purposes
    • H04W4/35—Services specially adapted for particular environments, situations or purposes for the management of goods or merchandise
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/30—Services specially adapted for particular environments, situations or purposes
    • H04W4/38—Services specially adapted for particular environments, situations or purposes for collecting sensor information
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Business, Economics & Management (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Accounting & Taxation (AREA)
  • Development Economics (AREA)
  • Finance (AREA)
  • General Engineering & Computer Science (AREA)
  • Strategic Management (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Signal Processing (AREA)
  • General Business, Economics & Management (AREA)
  • Economics (AREA)
  • Theoretical Computer Science (AREA)
  • Marketing (AREA)
  • Animal Behavior & Ethology (AREA)
PL14769752.8T 2013-03-15 2014-03-13 Aktywacja bioluminescencji przez dopełnienie strukturalne PL2970412T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791549P 2013-03-15 2013-03-15
PCT/US2014/026354 WO2014151736A1 (en) 2013-03-15 2014-03-13 Activation of bioluminescence by structural complementation

Publications (1)

Publication Number Publication Date
PL2970412T3 true PL2970412T3 (pl) 2022-11-14

Family

ID=51581027

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14769752.8T PL2970412T3 (pl) 2013-03-15 2014-03-13 Aktywacja bioluminescencji przez dopełnienie strukturalne
PL20197758.4T PL3783011T3 (pl) 2013-03-15 2014-03-13 Aktywacja bioluminescencji przez dopełnienie strukturalne

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL20197758.4T PL3783011T3 (pl) 2013-03-15 2014-03-13 Aktywacja bioluminescencji przez dopełnienie strukturalne

Country Status (15)

Country Link
US (11) US9797889B2 (enExample)
EP (4) EP4169935A1 (enExample)
JP (4) JP6654557B2 (enExample)
KR (3) KR20150129721A (enExample)
CN (2) CN105143249A (enExample)
AU (3) AU2014236949C1 (enExample)
BR (1) BR112015023394B8 (enExample)
CA (1) CA2906063C (enExample)
DK (2) DK2970412T5 (enExample)
ES (2) ES2929362T3 (enExample)
IL (3) IL286816B (enExample)
PL (2) PL2970412T3 (enExample)
PT (2) PT3783011T (enExample)
SG (2) SG10201601929YA (enExample)
WO (1) WO2014151736A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4169935A1 (en) * 2013-03-15 2023-04-26 Promega Corporation Activation of bioluminescence by structural complementation
EP4219736A1 (en) * 2014-09-12 2023-08-02 Promega Corporation Internal protein tags
US11365402B2 (en) 2014-09-12 2022-06-21 Promega Corporation Internal protein tags
EP4455668A3 (en) 2015-02-05 2025-02-19 Promega Corporation Luciferase-based thermal shift assays
US10634680B2 (en) 2016-04-26 2020-04-28 University Of Utah Research Foundation Target-binding activated split reporter systems for analyte detection and related components and methods
JP7227901B2 (ja) 2016-10-20 2023-02-22 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ ボツリヌス神経毒素の活性を測定するためのインビトロアッセイ法及び細胞ベースのアッセイ法
CA3022981C (en) * 2017-11-01 2025-05-06 Univ Kingston Hippo pathway bioluminescent biosensor
CN112352055A (zh) * 2018-02-26 2021-02-09 艾恩德霍芬技术大学 用于检测和定量溶液中的生物分子或配体的生物发光生物传感器
EP4140991B1 (en) 2018-06-01 2024-05-15 Promega Corporation Inhibitors of oplophorus luciferase-derived bioluminescent complexes
JP2021526832A (ja) * 2018-06-12 2021-10-11 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ 多分子ルシフェラーゼ
US10962538B2 (en) 2018-06-14 2021-03-30 The Trustees Of Columbia University In The City Of New York Assays using arrestin recruitment and unmodified receptors
JP7447101B2 (ja) 2018-10-03 2024-03-11 プロメガ コーポレイション セレンテラジンならびにその類似体及び誘導体を安定化させるための組成物及び方法
US11175228B2 (en) * 2018-11-28 2021-11-16 Promega Corporation Reactive peptide labeling
US20200200765A1 (en) 2018-12-04 2020-06-25 Promega Corporation Broad spectrum gpcr binding agents
US11913944B2 (en) 2019-03-20 2024-02-27 Promega Corporation Photoaffinity probes
BR112021020354A2 (pt) * 2019-04-10 2021-12-14 Promega Corp Composições e métodos para detecção de analito com o uso de bioluminescência
US11360096B2 (en) 2019-05-16 2022-06-14 Duke University Complex BRET technique for measuring biological interactions
JP7650829B2 (ja) 2019-06-24 2025-03-25 プロメガ コーポレイション 細胞中に生体分子を送達するための修飾ポリアミンポリマー
DE102019127894B4 (de) * 2019-10-16 2022-05-12 Sensor-Instruments Entwicklungs- Und Vertriebs-Gmbh Produktkennzeichnungssystem und verfahren zur kennzeichnung eines produkts
WO2021102434A1 (en) * 2019-11-22 2021-05-27 The Regents Of The University Of California Split-enzyme system to detect specific dna in living cells
JP7713448B2 (ja) 2019-11-27 2025-07-25 プロメガ コーポレイション 多分子ルシフェラーゼペプチド及びポリペプチド
WO2021119149A1 (en) 2019-12-10 2021-06-17 Promega Corporation Compositions and methods for bioluminescent detection using multifunctional probes
US20230211023A1 (en) 2020-03-25 2023-07-06 Erasmus University Medical Center Rotterdam Reporter system for radionuclide imaging
WO2021231498A2 (en) * 2020-05-11 2021-11-18 Chan Zuckerberg Biohub, Inc. Detection assay for anti-sars-cov-2 antibodies
US20210363565A1 (en) 2020-05-22 2021-11-25 Promega Corporation Enhancement of kinase target engagement
CN116391129A (zh) 2020-08-28 2023-07-04 普罗美加公司 针对ras蛋白的靶标接合测定法
WO2022245922A1 (en) * 2021-05-18 2022-11-24 The Board Of Regents Of The University Of Texas System Poly-adp ribose (par) tracker optimized split-protein reassembly par detection reagents
US20240174992A1 (en) 2022-05-04 2024-05-30 Promega Corporation Split modified dehalogenase variants
EP4519290A1 (en) 2022-05-04 2025-03-12 Promega Corporation Circularly permuted dehalogenase variants
US20230357266A1 (en) 2022-05-04 2023-11-09 Promega Corporation Photoactivatable compounds and uses thereof
US20240132859A1 (en) 2022-05-04 2024-04-25 Promega Corporation Modified dehalogenase with extended surface loop regions
WO2024151471A1 (en) 2023-01-09 2024-07-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High-throughput assay based on ligand-biased structural dynamics response
WO2024217577A1 (zh) * 2023-04-21 2024-10-24 深圳琅技生命科技有限公司 一种肽以及含有该肽的发光复合物
WO2024229422A2 (en) * 2023-05-04 2024-11-07 Promega Corporation Complementation-based tags and reporters for dual-modality labeling
WO2025064581A1 (en) * 2023-09-18 2025-03-27 The Brigham And Women’S Hospital, Inc. Biosensor platform for the rapid detection of analytes
WO2025158412A1 (en) 2024-01-26 2025-07-31 Biohaven Therapeutics Ltd. BIFUNCTIONAL DEGRADERS OF IgG4 IMMUNOGLOBULINS

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US5914095A (en) 1989-04-07 1999-06-22 Salutar, Inc. Polychelants containg amide bonds
US5756688A (en) 1992-10-14 1998-05-26 Sterling Winthrop Inc. MR imaging compositions and methods
EP0664819B1 (en) 1992-10-14 1997-08-06 Nycomed Imaging As Chelating polymers
GB9503969D0 (en) 1995-02-28 1995-04-19 Sams Bernard Incrementing mechanism
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US5879739A (en) 1997-02-20 1999-03-09 Tower Semiconductor Ltd. Batch process for forming metal plugs in a dielectric layer of a semiconductor wafer
EP1156103B1 (en) * 2000-04-26 2010-08-11 Chisso Corporation Oplophorus luciferase
JP4613441B2 (ja) * 2000-04-26 2011-01-19 チッソ株式会社 新規ルシフェラーゼおよび発光蛋白質
US20040181830A1 (en) 2001-05-07 2004-09-16 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US7008642B1 (en) 2001-02-12 2006-03-07 Advanced Cardiovascular Systems, Inc. Compositions for achieving a therapeutic effect in an anatomical structure and methods of using the same
US7195884B2 (en) 2002-07-19 2007-03-27 Promega Corp. Methods and kits for transferases
AU2003283995A1 (en) * 2002-09-30 2004-04-19 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
US7237811B1 (en) * 2005-04-20 2007-07-03 Lawrence Barry G Casement window latch assembly
EP1931787A4 (en) 2005-09-30 2010-10-20 Univ Montana State SYSTEM FOR DETECTING PROTEIN-PROTEIN INTERACTIONS
US7601517B2 (en) 2006-01-10 2009-10-13 Stanford University Split protein self complementing fragments, systems, and methods of use thereof
US20130332133A1 (en) 2006-05-11 2013-12-12 Ramot At Tel Aviv University Ltd. Classification of Protein Sequences and Uses of Classified Proteins
US20090075313A1 (en) 2007-05-04 2009-03-19 Stanford University Split protein fragments, split protein systems, methods of making split protein systems, and methods of using split protein systems
EP2210104A4 (en) 2007-11-01 2011-02-23 Univ Arizona State CELL-FREE PROCEDURE FOR DETECTING PROTEIN-LIGAND INTERACTIONS
EP2222328A4 (en) * 2007-11-15 2013-06-05 Endocyte Inc PROCESS FOR THE ADMINISTRATION OF CONJUGATES
WO2010090319A1 (ja) 2009-02-09 2010-08-12 チッソ株式会社 セレンテラジン類縁体及びその製造方法
EP2420573A1 (en) 2009-04-17 2012-02-22 National Institute of Advanced Industrial Science And Technology Stable artificial bioluminescent enzyme having super-high brightness
BRPI1010019B1 (pt) 2009-05-01 2019-02-05 Promega Corp polipeptídeo de luciferase modificada, vetor e kit compreendendo os mesmos
EP4012714A1 (en) * 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
JP5889910B2 (ja) * 2010-11-02 2016-03-22 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ 新規セレンテラジン基質及び使用法
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
US10024862B2 (en) * 2012-12-12 2018-07-17 Promega Corporation Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer
EP4169935A1 (en) 2013-03-15 2023-04-26 Promega Corporation Activation of bioluminescence by structural complementation
EP4219736A1 (en) * 2014-09-12 2023-08-02 Promega Corporation Internal protein tags

Also Published As

Publication number Publication date
US20200292534A1 (en) 2020-09-17
JP6654557B2 (ja) 2020-02-26
EP2970412B1 (en) 2022-08-10
EP4169935A1 (en) 2023-04-26
PL3783011T3 (pl) 2022-11-21
CA2906063A1 (en) 2014-09-25
AU2020213288A1 (en) 2020-08-27
CN105143249A (zh) 2015-12-09
US20160282340A1 (en) 2016-09-29
US20180095074A1 (en) 2018-04-05
BR112015023394B1 (pt) 2023-08-29
EP4177261A1 (en) 2023-05-10
IL273989B (en) 2021-10-31
JP2020097597A (ja) 2020-06-25
EP3783011B1 (en) 2022-09-21
IL240985A0 (en) 2015-11-30
DK2970412T3 (da) 2022-08-29
US20250022022A1 (en) 2025-01-16
EP2970412A1 (en) 2016-01-20
EP3783011A1 (en) 2021-02-24
JP7532562B2 (ja) 2024-08-13
WO2014151736A1 (en) 2014-09-25
US20140363375A1 (en) 2014-12-11
DK3783011T3 (da) 2022-10-17
DK2970412T5 (da) 2024-10-14
IL286816A (en) 2021-10-31
SG10201601929YA (en) 2016-04-28
US20180306782A1 (en) 2018-10-25
IL286816B (en) 2022-09-01
CA2906063C (en) 2025-10-07
PT2970412T (pt) 2022-09-13
AU2018256548A1 (en) 2018-11-22
ES2929362T3 (es) 2022-11-28
US12366572B2 (en) 2025-07-22
US12367513B2 (en) 2025-07-22
US9797889B2 (en) 2017-10-24
AU2014236949C1 (en) 2018-11-29
US20180313825A1 (en) 2018-11-01
AU2014236949A1 (en) 2015-09-24
AU2014236949B2 (en) 2018-08-02
BR112015023394A2 (pt) 2017-11-28
US20180196038A1 (en) 2018-07-12
US10648971B2 (en) 2020-05-12
KR20230079494A (ko) 2023-06-07
KR20150129721A (ko) 2015-11-20
JP2016519065A (ja) 2016-06-30
US20250045806A1 (en) 2025-02-06
US9869670B2 (en) 2018-01-16
US10107800B2 (en) 2018-10-23
PT3783011T (pt) 2022-10-26
KR102675860B1 (ko) 2024-06-20
KR20210036422A (ko) 2021-04-02
US20140348747A1 (en) 2014-11-27
AU2018256548B2 (en) 2020-05-14
AU2020213288B2 (en) 2022-07-07
US10184936B2 (en) 2019-01-22
JP7280842B2 (ja) 2023-05-24
US20230342826A1 (en) 2023-10-26
BR112015023394B8 (pt) 2023-09-26
IL273989A (en) 2020-05-31
JP2023055734A (ja) 2023-04-18
ES2926463T3 (es) 2022-10-26
US11493504B2 (en) 2022-11-08
CN117024548A (zh) 2023-11-10
US10288605B2 (en) 2019-05-14
US9797890B2 (en) 2017-10-24
JP2024167207A (ja) 2024-12-03
EP2970412A4 (en) 2016-07-27
SG11201507306VA (en) 2015-10-29
IL240985B (en) 2020-05-31
DK3783011T5 (da) 2024-08-19

Similar Documents

Publication Publication Date Title
NL301247I2 (nl) mirikizumab
PL2970412T3 (pl) Aktywacja bioluminescencji przez dopełnienie strukturalne
NO2021038I1 (no) lumasiran
DK3342773T3 (da) Syk-hæmmere
DK3613453T3 (da) Fordamper
DK2978844T3 (da) Modificerede tgf-beta2-oligonukleotider
DK3077047T3 (da) Aramcholsalte
DK3052081T3 (da) Pastil
DK3060460T3 (da) Saddel
HRP20171890T1 (hr) Supstituirani imidazopiridazini
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK2956698T3 (da) Bindestrimler
EP2945942A4 (en) Voriconazole IMMUNOASSAY
FR3003883B3 (fr) Plinthe
DK2946640T3 (da) Langmuir-probe
EP2943489A4 (en) DEUTERATED MOMELOTINIB
EP2969096A4 (en) Bottle pressurization delivery system
DE102013106534B8 (de) Chromatographiepipettenspitze
EP2991647A4 (en) DEUTERED AMLEXANOX
EP2970310A4 (en) 5-BROMO-indirubins
EP2853297A4 (en) kendama
DK3071227T3 (da) Fiskevaccine
DE112014001252A5 (de) Aufbissschiene
DK3086679T3 (da) Sportssko
DK2981168T3 (da) Laminitiskile